Cocrystal Pharma (COCP) Non-Current Deffered Revenue (2015 - 2018)
Cocrystal Pharma (COCP) posted Non-Current Deffered Revenue of $10000.0 for Q3 2018, down 41.18% sequentially from $17000.0 in Q2 2018, and down 72.97% YoY from $37000.0 in Q3 2017.
Cocrystal Pharma (COCP) Non-Current Deffered Revenue (2015 - 2018) Analysis & Trends
Cocrystal Pharma has reported Non-Current Deffered Revenue for 4 years, with the latest figure at $10000.0 in Q3 2018.
- Quarterly Non-Current Deffered Revenue fell 72.97% year-over-year to $10000.0 in Q3 2018, while the trailing twelve-month figure through Sep 2018 was $10000.0 (down 72.97% YoY) and the FY2017 annual result came in at $31000.0, down 50.79% from the prior year.
- Non-Current Deffered Revenue fell to $10000.0 in Q3 2018 per COCP's latest filing, from $17000.0 in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $63000.0 in Q4 2016 and troughed at $10000.0 in Q3 2018.
- A 4-year average of $38700.0 and a median of $39500.0 in 2017 frame the typical range for Non-Current Deffered Revenue.
- The sharpest annual moves came in 2016 and 2018: Non-Current Deffered Revenue gained 3.28% in 2016, then slumped 72.97% in 2018.
- Over 4 years, Non-Current Deffered Revenue stood at $61000.0 in 2015, then advanced by 3.28% to $63000.0 in 2016, then tumbled by 50.79% to $31000.0 in 2017, then tumbled by 67.74% to $10000.0 in 2018.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $10000.0, $17000.0, and $25000.0 for Q3 2018, Q2 2018, and Q1 2018 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cocrystal Pharma | 15.65 Mn | 13.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 10,000.00 |
| Jun 30, 2018 | 17,000.00 |
| Mar 31, 2018 | 25,000.00 |
| Dec 31, 2017 | 31,000.00 |
| Sep 30, 2017 | 37,000.00 |
| Jun 30, 2017 | 42,000.00 |
| Mar 31, 2017 | 47,000.00 |
| Dec 31, 2016 | 63,000.00 |
| Sep 30, 2016 | 54,000.00 |
| Dec 31, 2015 | 61,000.00 |